Quiver Bioscience Secures Non-Dilutive Funding to Enhance CNS Genetic Medicine Drug Discovery Platform Capabilities and Advance Powerful AI/ML-Based In Vitro / In Silico Predictor of CNS Drug Safety

▤ Summary

Quiver Bioscience received a $2.15 million SBIR Phase II grant from the NIH to expand its CNS genetic medicine discovery platform. The company will use the funding to improve prediction of safety and tolerability for antisense oligonucleotide therapeutics. It will combine human neuronal models, all-optical electrophysiology, and AI/ML analytics with in silico design tools and in vitro assays. The project aims to reduce reliance on animal studies, lower development costs, and speed up lead identification for CNS drug programs.

$ Funding

▦ Linked Companies